Drug Pricing Transparency Laws: Impact on Pharma Profitability
Over the past decade, the global pharmaceutical industry has come under increasing scrutiny for the way it prices its products. Governments, payers, employers, and patients are demanding greater visibility into how drug prices are set and why they continue to rise. In response, drug pricing transparency laws have emerged as a powerful regulatory tool aimed…
Hospital Revenue Cycle Optimization with Automation
The financial health of hospitals is increasingly under pressure. Rising operational costs, shifting reimbursement models, complex payer requirements, and growing patient expectations have turned revenue cycle management into a strategic priority rather than a back-office function. In this evolving landscape, automation is emerging as a transformative force—one that is redefining how hospitals capture, manage, and…
Study Suggests Novo Nordisk’s Weight-Loss Drug May Better Preserve Muscle Than Lilly’s Tirzepatide
A new study indicates that Novo Nordisk’s semaglutide may preserve lean body mass more effectively than Eli Lilly’s tirzepatide, despite the latter delivering greater overall weight loss. The analysis, conducted by data firm nference, reviewed outcomes from approximately 8,000 patients and found that tirzepatide users experienced consistently higher loss of lean body mass—including muscle and…
ICER Urges Greater Transparency in FDA’s Accelerated Drug Approval Process
The Institute for Clinical and Economic Review (ICER) has called on the U.S. Food and Drug Administration (FDA) to improve transparency in its accelerated drug approval pathway, citing ongoing concerns about evidence standards and follow-through on clinical validation. The accelerated approval program is designed to fast-track treatments for serious conditions lacking effective therapies. It allows…
FDA Considers Expanding Testosterone Therapy Use for Low Sex Drive in Men
The U.S. Food and Drug Administration is evaluating a proposal to broaden the use of testosterone replacement therapy to treat low sex drive in men with unexplained low hormone levels. Currently, testosterone therapy is approved only for men whose low testosterone is linked to identifiable structural or genetic causes. The proposed expansion would extend eligibility…
OpenAI Launches GPT-Rosalind to Accelerate AI-Driven Life Sciences Research
OpenAI has introduced GPT-Rosalind, a new artificial intelligence model designed specifically for life sciences research, marking a deeper push into biochemistry, drug discovery, and translational medicine. Named after pioneering scientist Rosalind Franklin, the model is built to support complex scientific workflows, including evidence synthesis, hypothesis generation, and experimental planning. The launch reflects growing demand for…
Eli Lilly’s Foundayo Pill Cuts Heart Attack and Stroke Risk in Late-Stage Study
Eli Lilly’s Foundayo Pill Cuts Heart Attack and Stroke Risk in Late-Stage Study Eli Lilly has reported that its newly approved oral obesity drug, Foundayo, significantly reduces the risk of major cardiovascular events in patients with type 2 diabetes and obesity, according to late-stage clinical trial results. The study found that Foundayo lowered the risk…
Trump Expected to Announce CDC Director Nominee, Kennedy Says
Robert F. Kennedy Jr. indicated that Donald Trump is likely to announce a nominee for the director of the Centers for Disease Control and Prevention (CDC) within the next day. Speaking before the House Appropriations health subcommittee, Kennedy said he expects the administration to unveil nominations for a broader leadership team at the CDC, including…
Gerresheimer Rejects Takeover Approach from Silgan, Ends Discussions
Gerresheimer has rejected a takeover bid from U.S.-based rival Silgan, with sources indicating that discussions between the two companies have now ceased. The development follows earlier reports that Silgan had submitted a non-binding offer of approximately €41 per share—more than double Gerresheimer’s prevailing share price at the time. Despite the premium valuation, Gerresheimer has opted…
Kennedy touts new food policies but avoids vaccines in remarks to US Congress
Robert F. Kennedy Jr. focused on nutrition and food safety initiatives during recent appearances before the United States Congress, while largely avoiding questions related to his controversial stance on vaccination policy. Testifying before the House Ways and Means Committee and the Appropriations health subcommittee, Kennedy outlined elements of the Trump administration’s proposed 2027 health budget…
Gene Editing Breakthrough Hints at Potential Down Syndrome Treatment, While Scientists Advance Immune Reprogramming
Researchers are exploring a promising new approach to treating Down syndrome using an advanced form of CRISPR, alongside parallel breakthroughs in reprogramming the immune system to produce rare, high-value antibodies. Silencing the Extra Chromosome A research team led by Volney Sheen has developed a modified CRISPR technique that, in early laboratory experiments, shows potential to…
AI ROI in Healthcare: Measuring Value Beyond Cost Savings
Artificial intelligence is rapidly becoming embedded in healthcare systems—from clinical decision support and imaging analysis to revenue cycle management and patient engagement. As adoption accelerates, one question continues to dominate boardroom discussions: what is the return on investment? Traditionally, ROI has been framed in financial terms—cost savings, efficiency gains, and reduced labor. While these metrics…